Podcast appearances and mentions of Richard Kim

Dr. Shaalan Beg and Dr. David Wang discuss key abstracts in GI cancers from the 2025 ASCO Gastrointestinal Cancers Symposium, including major advances in CRC, neoadjuvant approaches in esophageal cancer, and innovative studies on ctDNA. TRANSCRIPT Dr. Shaalan Beg: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas. Today, we're bringing you some key highlights from the 2025 ASCO Gastrointestinal Cancers Symposium, and I'm delighted to be joined by the chair of GI25, Dr. David Wang. Dr. Wang is a GI medical oncologist at the University of Michigan. Our full disclosures are available in the transcript of this episode.  Dr. Wang, thanks for coming on the podcast today. Dr. David Wang: Well, thank you. It's a pleasure to be here. Dr. Shaalan Beg: GI25 featured major therapeutic advances across the spectrum of GI malignancies, and it was exciting to hear about innovations and novel approaches that are shaping the future of our field. Before we start talking about specific abstracts, could you share some of your key highlights from the meeting? Dr. David Wang: Sure. Our theme this year was “Breaking Boundaries to Enhance Patient Centered Care.” Past years' themes have focused more on precision oncology, but we wanted to broaden our focus on patients and to be more holistic, which kind of led us into some of the Intersection [sessions] that we had. Each day started with a different Intersection. The first one was “Emerging Therapies in GI Cancers”, where invited speakers talked about bispecific antibody drug conjugates, theranostics, CAR T and other cell-based therapies. The second day was on “Personalized Risk Assessment for GI Cancers,” and this included looking at polygenic risk scores for colorectal cancer, microRNAs and liquid biopsies such as exosomes and pancreatic cancer and non-endoscopic screening modalities in esophageal cancer. And on our final day, we wanted to talk about “Integrative Oncology and Integrative Medicine,” looking at evidence-based uses of acupuncture and supplements in patients who are receiving treatment for cancer, mindfulness-based practices and exercise. And of course, we had a fantastic keynote talk by Dr. Pamela Kunz from the Yale School of Medicine titled, “Disrupting Gastrointestinal Oncology: Shattering Barriers with Inclusive Science.” She highlighted the intersection of science, patient care, and health and gender equity. And I would encourage your podcast listeners to access the lecture in ASCO's Meeting Library if they haven't yet had a chance to hear Dr. Kunz's wonderful lecture.  We were really happy this year because the attendance hit a new record. We had over 5,000 people attend either in person or virtually from their home or office, and we had almost 1,000 abstracts submitted to the meeting, so these were either record or near record numbers. We offered a lot of different networking opportunities throughout the meeting, and attending found these to be incredibly rewarding and important and this will continue to be an area of emphasis in future meetings. Dr. Shaalan Beg: Let's take a deeper dive into the exciting studies presented at GI25. The late breaking abstract LBA143 was CheckMate-8HW. This was the first results of NIVO + IPI versus NIVO monotherapy for MSI-high metastatic colorectal cancer. What are your thoughts about this study? Dr. David Wang: Yeah, so we know that colorectal cancer patients with MSI-high tumors don't necessarily respond well to chemotherapy. And we were fortunate because last year CheckMate-8HW actually looked at two different arms – so this was NIVO + IPI compared to standard of care chemotherapy and showed its very significant improvement in median progression-free survival. And that was actually published in the New England Journal of Medicine back in November of 2024. This year's presentation actually focused now on NIVO + IPI versus NIVO monotherapy. And as you know IPI+NIVO can be quite toxic. So this was an important analysis to be done. So we know that NIVO is definitely more easily tolerated. So what was interesting was that the 2-year and 3-year progression-free survival not surprisingly favored IPI+NIVO and this was statistically significant. And the overall response rate was also better with IPI+NIVO versus NIVO alone. I know we're always concerned about toxicities and there were higher grade 3 and 4 toxicity incidences in the combination arm versus the monotherapy arm, but overall, only about 28 additional events in several hundred patients treated. So I think that's well-tolerated. Our discussant Dr. Wells Messersmith actually said that, with this new data, he would consider doing combination immunotherapy in any patient that presented in the front line with MSI-high or deficient mismatch repair colorectal cancer that was metastatic. Dr. Shaalan Beg: One of the focuses for directing first-line therapy for colorectal cancer has been right and left sided colon cancer because we know these are two different cancers with their own unique molecular subtypes. We heard on Abstract 17, the DEEPER trial, the final analysis of modified FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left sided metastatic colorectal cancer. How do you summarize the findings of this study and what should our readers be aware of? Dr. David Wang: Interestingly, this was a phase 2 study and the emphasis of the abstract was actually a subgroup analysis of those patients with RAS wild-type and BRAF wild-type as well as left sided cancers. So, I think the entire study enrolled 359 patients, but the analysis that was discussed at the meeting really focused on 178 patients that fit that characteristic. Very similar to what we've seen in prior studies, left-sided tumors have better response to cetuximab versus bevacizumab. And if you flip it so that you now are looking at right sided tumors, targeting EGFR is actually detrimental. The depth of response was better with cetuximab in these left sided RAS and BRAF mutant tumors. And so the lead author actually suggested that this could be a new first-line standard of care. And the question is, is there a benefit of doing this triple agent regimen with modified FOLFIRINOX? We know there's a lot more toxicity with that. Not clear that there's a benefit for that over FOLFOX, maybe in younger patients that could tolerate it. When our discussant, again Dr. Wells Messersmith, spoke about this, he said that, in his practice he would, again, favor cetuximab over bevacizumab in combination with chemo, these left-sided RAS and BRAF wild-type tumors, but that he would actually prefer a doublet versus a triplet chemo regimen, and that is consistent with the current NCCN guidelines. Dr. Shaalan Beg: Another area where colorectal cancer has been a wonderful model to study new technology has been in the area of circulating tumor DNA (ctDNA). And the BESPOKE CRC trial is looking to see if ctDNA can inform adjuvant treatment decisions for stage II and III colorectal cancer. And in Abstract 15, we heard final results of the BESPOKE CRC sub-cohort. What were the findings there? Dr. David Wang: BESPOKE CRC is another one of these important ctDNA studies. It was an observational study, not a randomized trial, but it did provide a lot of different insights to us. We know that there were over 1,700 patients enrolled, and so it was reported that this is the largest ctDNA study in colorectal cancer performed in the United States. And they were able to analyze over 1,100 patients.  Some of the key findings were that postoperative adjuvant therapy management decisions actually changed in 1 out of 6 patients, so that's pretty significant. In terms of surveillance, we know that patients who have ctDNA positivity, this is prognostic of recurrence. In terms of patients who have positive ctDNA post-surgery, it looked like, at least in this observational study, the majority of patients who received any benefit were those who had positive ctDNA. So adjuvant therapy, even in stage II and stage III patients seemed to only benefit those patients who have positive ctDNA. I think that does raise the question, and this also was brought up in the discussion, which is “Can we de-escalate adjuvant therapy in terms of patients who are ctDNA-negative post-op?” And Dr. Richard Kim from Moffitt felt that we are not yet there. Obviously, we need randomized control trials where we are taking ctDNA results and then randomizing patients to receive adjuvant or non-adjuvant to really know the difference.  Other questions that come up with use of ctDNA include: What do you do with these patients who turn positive? This study for BESPOKE actually followed patients out to two years after surgery. So what you do with a positive ctDNA result wasn't really clear. It seems to suggest that once you turn positive, patients go on to more intensive surveillance. You know, again as an observation, patients who did turn positive were able to go to metastasis-directed therapy much more quickly. And again, this was supposedly to improve their curative intent therapy. And I think the other question that has been brought up all the time is, is this really cost effective? Patients want to know, and we want to give patients that information, but I think we're still stuck with what to do with a positive ctDNA level in a patient that's on surveillance because no randomized control studies have actually suggested that we need to start systemic therapy right away. Dr. Shaalan Beg: Yeah. And I guess in terms of practice informing or practice changing, these results may not give us a clear answer. But because a lot of patients are asking for these tests, it does give us some real world experiences on what to expect in terms of conversion of these positive into negative and the outcome so we can have a shared decision making with our patients in the clinic and then come up with a determination on whether ctDNA for molecular residual disease is something which would be worthwhile for the care of our patient. But more to come, I guess, in coming years to answer different problems around this challenge. Dr. David Wang: Yes, I agree. Dr. Shaalan Beg: The BREAKWATER trial looked at the use of encorafenib, cetuximab and chemotherapy for BRAF V600E-mutant metastatic colorectal cancer. We've covered this combination for a second- third-line treatment in metastatic colorectal cancer previously. Abstract 16 from GI25 was evaluating the use of this regimen in the first-line space. Everyone was looking forward to these results, and what did the investigators present? Dr. David Wang: I think this is, as you mentioned, a nice follow up to later lines of therapy where Dr. Kopetz from MD Anderson pioneered use of encorafenib, cetuximab and binimetinib in the BEACON trial. Everybody was kind of curious what would happen now if you use encorafenib plus cetuximab plus chemotherapy in the first-line setting. And so this is an interim analysis that was pre-planned in the phase 3 open label BREAKWATER trial. And even though there were three arms, and so the three arms were encorafenib plus cetuximab, encorafenib plus cetuximab plus FOLFOX, or standard of care chemo, only two arms were presented in the abstract. So basically looking at encorafenib plus cetuximab and FOLFOX-6 versus standard of care therapy, and the overall response rate was statistically significant with a 60.9% overall response rate encorafenib plus cetuximab plus chemo arm versus standard of care chemo was only 40%. The interim overall survival also was different. It was 92% versus 87% at 6 months and 79% versus 66% at 12 months, again favoring the chemotherapy plus encorafenib plus cetuximab. In terms of the statistics, the p was 0.0004. However, the pre-plan analysis required the p-value to be 1x10 to the -8. And so even though this looks really good, it hasn't quite met its pre-specified significance level. The good thing is that this is only interim analysis and the study is ongoing with future analysis planned.  So the real question is: Does it matter when we actually use this regimen? We know that the regimen's approved in the second third-line setting. What about in the first line? And there was some preclinical data that the discussant reviewed that shows that patients actually benefit if this is done in the first-line setting. For example, there was some preclinical data showing that even FOLFIRI, for example, can upregulate RAS, which would make tumors more resistant to this combination. This was thought to be practice-changing in a patient that has B600E showing up treatment naive that we should probably consider this regimen. And actually this did receive accelerated FDA approval about a month ago. Dr. Shaalan Beg: Yeah, and for what it's worth, I put up a Twitter poll asking my Twitter followers on how the BREAKWATER trial results will change their approach for newly diagnosed BRAF mutated colorectal cancer. We got 112 responses; 72% said that they will incorporate encorafenib, cetuximab, FOLFOX for their frontline BRAF mutated patients. But 23% said that they would like to wait for overall survival results. Dr. David Wang: Wow, that's interesting. They really want that 1x10 to the -8. Dr. Shaalan Beg: I guess so. All right. Let's change gears and talk about esophageal cancer. LBA329 was the SCIENCE study which presented preliminary results from a randomized phase 3 trial comparing sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant resectable locally advanced squamous esophageal cancer. Where are we in this space? Dr. David Wang: Okay. So, yeah, this was an interesting trial. Again, just to set the context, esophageal squamous cell carcinoma is more prevalent in Asia. And the study sites as well as the patients were mostly from Asia. So this was again a phase 3 trial with interim results. They only rolled 146 out of the planned 420 for this interim analysis. And yeah, they're using immune checkpoint inhibitor that we don't use in the United States, sintilimab, combined with their two standards of neoadjuvant therapy, either chemotherapy, which is more common in Asia, or or chemoradiation, which is more common in the US and Western Europe, versus chemoradiation. And so they actually had two primary endpoints, but only were reporting one. So their two primary endpoints were pathCR and the other one was event-free survival. The event-free survival, again, was not reported at the meeting.  What they found was that in terms of pathCR rate, if you take the two arms that are really informative about that, chemoradiation plus sintilimab versus chemoradiation alone, the pathCR rate was 60% versus 47%. We know that chemo alone doesn't induce as much of a pathCR rate, and that was 13%. So it was found that the delta in terms of pathCR between the chemoradiation arms, one with sintilimab and one without, was significant. And this actually confirms data again from Asia, like for the ESCORT-NEO trial where it used another immune checkpoint inhibitor pembrolizumab in addition to neoadjuvant chemo.  So as our discussant for this abstract said, yes, we know that radiation combined with chemotherapy improves pathCR rates, but we have recent data from the ESOPEC trial, we don't know that that necessarily will translate to overall survival. So again, waiting for additional enrollments and longer term follow up before incorporating this into clinical care here. Dr. Shaalan Beg: So David, how do the results of the SCIENCE trial compare with our practice in the United States and ongoing studies asking questions for neoadjuvant therapy for esophageal carcinoma in the United States? Dr. David Wang: I think obviously immune checkpoint inhibitor in the new adjuvant setting is important. Jennifer Eads at UPenn is running that EA2174 which is looking at chemoradiation plus or minus nivolumab, and then in non-pathCR responders randomized to adjuvant nivolumab per CheckMate 577 or nivolumab with intensification adding ipilimumab. We know that the ESOPEC trial just came out, and was published actually during the meeting, and that really focuses on adenocarcinomas. So adenocarcinomas of the GE junction, distal esophagus, now, we would probably treat very similarly to gastric using perioperative FLOT. However, the standard in the US for esophageal squamous cell carcinoma remains neoadjuvant chemoradiation. We know that squamous cell carcinomas are more exquisitely sensitive to radiotherapy. And then obviously in those patients who don't achieve a pathologic complete response, the expectation would be that they would go on to receive nivolumab per CheckMate 577. Again, the thought is that these tumors are more sensitive to immunotherapy given their higher incidences of mutational changes. And so again, this kind of goes along with the positive results seen in the SCIENCE trial that we just discussed with sintilimab but also EFFECT-neo with pembrolizumab. Obviously, we await the results of Jennifer's trial. Dr. Shaalan Beg: And the last abstract I was hoping we could get your perspective on was Abstract 652, which is a Phase 3 study of everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumors, the STARTER-NET trial. What were the results of this study? Dr. David Wang: So, I just want to give a shout out because we did have a session at this year's GI ASCO that looked at more rare tumors. So appendiceal tumors, neuroendocrine tumors, those kinds of things. So again, I would encourage your listeners to listen to that session if they have interest in that. Another type of rare tumor was adenosquamous tumors.  But in terms of the STARTER-NET trial, this was again an interim analysis of his phase 3trial and it was looking at combining everolimus plus lanreotide versus everolimus. So we know that in pancreatic-gastric neuroendocrine tumors, if you have low Ki-67, a well differentiated tumor, that the standard of care really is a somatostatin analog, and sometimes if they're more aggressive, we kind of consider molecular targeted therapy with everolimus. This was asking the question of whether we should do the combination on the frontline. And what was interesting is in this study, the patients were actually more of a poor prognostic set. So they had Ki-67 up to 20% or these were patients that actually had multiple liver lesions. And what they found was a median for progression free survival was improved with a combination out to 29.7 months versus 11.5 months with the somatostatin analog alone, and that the overall response rate was 23% versus 8.3%, again, favoring the combination. If you looked at subgroup analysis, it was actually those patients who had Ki-67 greater than 10%, so the more aggressive tumors, or those with diffuse liver lesions that had the most benefit. So I think that would be the patient population I would consider this new combination with using would be those patients again with poorer prognosis neuroendocrine tumor phenotype. Dr. Shaalan Beg: Thank you very much, Dr. Wang, for sharing your insights with us today and your great work to build a robust GI Cancers Symposium this year. Dr. David Wang: Well, thank you. I mean that really is a cooperative effort. We appreciate all the members of the GI25 Program Committee as well as the ASCO staff that just made it an outstanding meeting. Dr. Shaalan Beg: And thank you to all our listeners for your time today. You'll find links to the abstracts discussed today on the transcript of this episode.  Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. Shaalan Beg @ShaalanBeg  Dr. David Wang Follow ASCO on social media:   @ASCO on Twitter  @ASCO on BlueSky ASCO on Facebook   ASCO on LinkedIn   Disclosures:  Dr. Shaalan Beg:  Employment: Science 37  Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine  Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals  Dr. David Wang: Honoraria:  Novartis Consulting or Advisory Role: Novartis, Cardinal Health, Bristol-Myers Squibb, BeiGene, Eisai  

Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts

Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts

Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts

Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts

Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer

Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer

Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer

Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer

Paywatch is a financial services company that provides earned wage access (EWA) services to help employees get banked, receive credit, and improve their access to financial products.Richard Kim, Co-Founder and CEO of Paywatch, founded the business in 2019 with his brother Alex. Together, they have built Paywatch as the only bank-backed and regulator-approved Earned Wage Access solution in Asia. Today, they have expanded their business not only in Malaysia and South Korea but also in other Asia Pacific countries like the Philippines and Indonesia, with their eyes set on Thailand and Vietnam ahead.As of June, Paywatch had processed over $58 million in salaries through its system and was growing month-over-month by as much as 15%. Their user base is spread across South Korea, Malaysia, the Philippines, and Indonesia, with notable clients including KFC, Pizza Hut (part of QSR Brands), Wilmar International, PayNet, and Jaya Grocer, among others.Last month, Paywatch raised US$30 million (approximately RM141 million) in funding from a mix of equity and credit facilities to continue its growth and expansion plans.In this conversation, Richard will give us a sense of why he started Paywatch, the problem he aims to address, the business opportunities present, the challenges in turning it into reality, and their growth path ahead.

Please visit answersincme.com/TSH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of metastatic colorectal cancer (mCRC) discuss sequencing strategies to enhance patient quality of life during later-line treatment. Upon completion of this activity, participants should be better able to: Describe the latest data for later-line treatment sequencing for patients with mCRC; Outline evidence-based strategies to optimally sequence later-line treatment options for mCRC; and Explain tactics for addressing quality of life and survivorship with patients in later lines of treatment for mCRC.

Guest host Richard Kim, THE CITY's editor in chief, talks to journalists Kai Wright and Lizzy Wright about their Blindspot podcast digging into the early years of the HIV/AIDS epidemic and focusing on overlooked populations including intravenous drug users, incarcerated people, and the pediatric patients separated from their families "who lived and died their entire lives on the ward of Harlem Hospital" — and the individuals and communities who stepped up and stepped in where institutions failed.

Paywatch plans to extend its reach to more of Asia's workforce and promote financial inclusion by leveraging Visa's cross-border capabilities, network and financial literacy and digital education content. Full discussion with it's CEO and Co-founder, Richard Kim.

Paywatch plans to extend its reach to more of Asia's workforce and promote financial inclusion by leveraging Visa's cross-border capabilities, network and financial literacy and digital education content. Full discussion with it's CEO and Co-founder, Richard Kim.

Tapestry LA continues the "The Gospel of John" sermon series. Richard Kim speaks from John 13:31-38 on Jesus' new commandment to love one another as he did.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Richard Kim, MD Guest: Benjamin A. Weinberg, MD Sadly, colon cancer is a very common cause of cancer-associated death in the United States. However, things may be looking up as data from ongoing trials is uncovered. Explore metastatic colorectal cancer (mCRC) further with Dr. Charles Turck as he speaks with Dr. Richard Kim, Service Chief of Medical Gastrointestinal Oncology at Moffitt Cancer Center in Tampa, Florida, and Dr. Benjamin Weinberg, Associate Professor of Medicine and Attending Physician specializing in Gastrointestinal Medical Oncology and Sarcoma at MedStar Health in Washington, DC.

Flexible pay access, also known as instant pay, is becoming increasingly popular as inflation creeps up and workers struggle to make ends meet. This allows employees to access a portion of their earned wages before payday, which can be a lifesaver for those who are struggling to cover unexpected expenses. We speak with Richard Kim from Paywatch about how flexible pay access helps improve employee satisfaction and reduce turnover, as well as how it can be a valuable ESG measure for businesses.Photo Credits: Paywatch

Dr. Richard Kim is the owner of Richard Kim Medicine. With offices located throughout New York State Dr. Kim practices nonsurgical orthopedic and regenerative medicine using stem cell therapy to help those with injuries heal their own bodies. He's also the team physician for USA Rugby. Sponsors: ANCORE. Named the best portable cable machine by Men's Health Home Gym Awards. Head over to ancoretraining.com/cdsf10 and use promo code CDSF10 for $50 off your order today. Drink Alchemy. By combining the most potent organic nootropics found in nature – Drink Alchemy delivers sustainable boosts to creativity, memory, energy, & focus in one epic beverage. Enjoy the benefits of real ingredients, natural nootropics, and live with your Mind Unbound by going to drinkalchemy.co and use code CDSF at checkout for 10% off your order today.

On this episode, host Jian DeLeon speaks Richard Kim of Galaxy Interactive, whose mission is to invest in content, social networks, and technology that fosters meaningful connection, engagement, and opportunity in the digital realm. His Art Blocks NFT collection — which will be on view during Hong Kong's most ambitious NFT showcase, METAVISION at K11 MUSEA — focuses on generative art, in which the work has been created with the use of an autonomous system. We talk about the basics of generative art, how to filter out the noise of the marketplace, and creating your own sense of community within the space.

As part of its Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, hematologist and medical oncologist at Florida Cancer Specialists in Fort Myers, Florida and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer. In the video series, Bustamante and Kim discussed the following: ·      Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases ·      Key Takeaways: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases ·      ctDNA as a Biomarker in CRC ·      ctDNA Assays in CRC: Interpreting Clinical Findings ·      ctDNA Assays in CRC: Impact on Clinical Practice ·      Next Steps in Using ctDNA as a Biomarker in CRC ·      Recap: Prognostic Potential of ctDNA for Oligometastatic Colorectal Cancer To watch more videos in CancerNetwork®'s Between the Lines™ series, visit cancernetwork.com/between-the-lines. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

What different views on human nature inform ethical theory in the Confucian tradition? What kinds of rituals do Confucians think we need to engage in to achieve flourishing lives or high levels of well-being? What kinds of rituals today might be inhibiting our flourishing and moral growth? -- a Discussion with Richard Kim about his book Confucianism and the Philosophy of Well-being.

How do non profit newsrooms thrive? Richard Kim, the new Editor-in-chief of TheCity.nyc joins us to discuss his new position, the world of nonprofit newsrooms and how they can compete with their big money counterparts.

How do non profit newsrooms thrive? Richard Kim, the new Editor-in-chief of TheCity.nyc joins us to discuss his new position, the world of nonprofit newsrooms and how they can compete with their big money counterparts.

Population growth in virtual worlds surpasses that of any nation today, a trend of keen interest to Richard Kim, general partner at Galaxy Interactive, unit of Mike Novogratz's Galaxy Digital Asset Management. Under Kim's guidance, Galaxy Interactive is the Lewis and Clark of the virtual frontier. “Self-sovereign digital natives,” as Kim refers to them, are people who have partially grown up in virtual environments and/or spend the majority of their spare time in them. Today, they're mostly younger people, through Web 2.0 platforms like Fortnite and Roblox. The next phase – into the “Metaverse” – is about user empowerment. Kim is also eyeing DAO governance in the world of gaming. It's still in the experimental phase. But the potential for a community-driven game – where development decisions are made by the people playing it – already marks a major shift from the status quo. Interviewed by Ash Bennington on February 1, 2022.

In this week's episode of Autology, IHS Markit experts discuss battery technology and the battery market. With a basic understanding of how NCM (nickel, manganese, cobalt) and LFP (lithium, iron phosphate) batteries work we dive deeper into the importance and implications of different cathode materials in battery technology. We also look into how these types of cathode materials are used in the downstream market and market leaders in LFP battery manufacturing. And finally, what might be the mid and longer term expectations for the growth of LFP or NCM cathode materials? Tune in to find out the answers, and much more! Speakers: Dr. Richard Kim, battery research expert at IHS Markit Dr. Youmin Rong, battery research expert on clean energy technology at IHS Markit We'd love to hear your thoughts on this episode at our autology@ihsmarkit.com email, and you can find out much more across the autotechinsight.ihsmarkit.com website.

Sam Englebardt is a co-founder and partner at Galaxy Digital, and is the founding general partner of Galaxy Interactive, which invests in next-generation interactive entertainment. He is also a content producer of film and television, working in a broad range of traditional & digital businesses. Richard Kim is a general partner at Galaxy Interactive, after a stint as COO at Galaxy Digital. These two guests are getting their hands dirty as the gaming, cultural, and technological worlds converge into the Metaverse. Trying to predict, invest, and help build this emerging phenomenon is a massive endeavor, but it's one that we need to get right. Exploring what the Metaverse actually is, how today's internet compares to the digital worlds of the future, and optimizing the user experience comprise the core of this discussion—but we open it to understanding the skeptics in the space, as well game economies and tokenomics. Sam and Richard expect to see a mass exodus into the Metaverse over the next couple decades… how are you going to play the Metaverse game? ------

Today, my guests are Sam Englebardt and Richard Kim, general partners at venture fund, Galaxy Interactive. Having come from the media and finance sectors, respectively, Sam and Richard joined forces in 2018 to invest in their shared thesis that immersive digital experiences would become the dominant way people engage with each other in the future.   Our conversation centers around the evolution of art, finance, and gaming as they proliferate in Web3. Please enjoy my conversation with Sam and Richard.     For the full show notes, transcript, and links to mentioned content, check out the episode page here.   -----   This episode is brought to you by Canalyst. Canalyst is the leading destination for public company data and analysis. If you're a professional equity investor and haven't talked to Canalyst recently, you should give them a shout. Learn more and try Canalyst for yourself at canalyst.com/Patrick.   -----   This episode is brought to you by Levels. As one of their early access members, Levels was one of the most interesting products I've ever used. Levels is attempting to make continuous glucose monitoring mainstream by using real-time biosensors to see how food affects your health. If you want early access to become a Member of their private Beta, (the waitlist is currently at 150K+ people), use this link – levels.link/PATRICK   ----- Invest Like the Best is a property of Colossus, LLC. For more episodes of Invest Like the Best, visit joincolossus.com/episodes.    Past guests include Tobi Lutke, Kevin Systrom, Mike Krieger, John Collison, Kat Cole, Marc Andreessen, Matthew Ball, Bill Gurley, Anu Hariharan, Ben Thompson, and many more.   Stay up to date on all our podcasts by signing up to Colossus Weekly, our quick dive every Sunday highlighting the top business and investing concepts from our podcasts and the best of what we read that week. Sign up here.   Follow us on Twitter: @patrick_oshag | @JoinColossus   Show Notes [00:02:50] - [First question] - Their thoughts on the digital art market [00:11:33] - What motivates traditional art collectors and what has been carried over into digital art [00:17:27] - Is there an attractive beta opportunity in the digital art space? [00:24:32] - Why investors should do more work understanding NFTs and ways to consider incorporating them into your portfolio [00:27:55] - The history of Galaxy and their thesis writ large  [00:33:09] - Exciting and terrifying aspects of the financialization of everything [00:37:27] - Places where inserting markets could be beneficial with Web3 [00:45:27] - Their perspectives on gaming as a subcategory of Web3 [00:51:38] - Tokenomics and the importance of building great game communities [00:59:18] - What we can learn from successful gaming companies and in-game monetization [01:04:19] - How Diablo 3's auction house detracted from the core player experience [01:06:36] - Where they disagree with the Web3 investing community [01:10:37] - The kindest things anyone has ever done for them

1 Bookie J-Zone 03:22 J-Zone & Pablo Martin are The Du-Rites2 There's a Creator Roscoe Robinson 03:15 Holy Spirit, Spiritual Soul & Gospel Funk from Shreveport's Jewel Records CD23 You've Got To Save Me Laura Lee 03:17 The Hot Wax-Invictus Anthology4 Halfway To Paradise Dobby Dobson 03:11 Something Old Something New5 Take Me In Your Arms (Rock Me A Little While) Kim Weston 02:56 The Complete Motown Singles, Vol. 5: 19656 A Lot Of Love Homer Banks 02:40 Kent's Cellar Of Soul7 A Knife And A Fork Kip Anderson 03:14 Chess Club Rhythm & Soul8 Savin' It All For You Judy Clay 02:17 Atlantic 26979 The Good Ol' Days Bobby Patterson & The Mustangs 02:34 Jetstar 11210 Fairly Well Larry Birdsong 02:17 The ref-o-ree Records Story - Southern Soul11 Wet Match Denise LaSalle 03:20 The Last Soul Company, Malaco (Disc 5 of 6)12 Drink O'Clock Beverley Skeete 04:15 Beverley Skeete - Woman Got Soul13 Loving You Is Sweeter Than Ever Ruthie Foster 04:15 Joy Comes Back14 It's a Wonder Curtis Harding 03:57 If Words Were Flowers15 Such A Night Esther Phillips 03:23 Performance16 Point Of View Matumbi 03:27 Point Of View17 Across the City Freedom or Not 05:29 Across the City18 We Should Be Dancing New Cool Collective & Mark Reilly 04:16 The Things You Love19 Right On for the Darkness Curtis Mayfield 07:30 Back to the World CD420 El Cuarto De Tula (feat. Maikel Ante, El Medico & Turbulence) Mista Savona 05:41 Havana Meets Kingston21 Sound Of Everything feat. Alice Russell Quantic 04:03 Mishaps Happening22 Right On Brand New Heavies, The 04:06 Get Used To It [bonus Tracks]23 Bougé Bagay La Guts 04:25 Philantropiques24 Gtfa Hackney Colliery Band 03:48 Hackney Colliery Band25 Soul Power 74 Maceo Parker 04:10 Us26 Mother Popcorn Osaka Monaurail 03:32 State Of The World27 Super Groupie Junie Morrison 05:22 Funk 'n Roll - A Collection of 70's Rare Funky Trips28 Rock it Nils Landgren Funk Unit 02:54 FONK DA WORLD29 She's a Winner Neal Francis 05:07 Changes30 Funk The Rich (Album Mix) Malente feat. Richard Kim 03:26 No Risk No Funk31 Wake Up Everybody Teddy Pendergrass 07:32 The Real... Teddy Pendergrass Disc 1

Dr. Young Richard Kim, a Classics and History professor at UIC, joins Lexie to talk about the dignity of work, the intersection of personal religion and the academic study of ancient religion, being Asian in Classics, and drops some hot takes on how to change the way we teach US/ancient world history in high schools. So tuck in your togas and hop aboard Trireme Transit for this week's exciting odyssey! Learn more about Dr. Kim: https://clasmed.uic.edu/profiles/kim-young/ Follow Dr. Kim on Twitter: @YoungRichardKim Check out the Asian and Asian American Classical Caucus: https://www.aaaclassicalcaucus.org Support us on Patreon: https://www.patreon.com/TheOzymandiasProject  Get exclusive bonus content (ad free episodes, early releases, and experimental content) on Patreon! Hosted on Acast. See acast.com/privacy for more information.

Creativity Conversations with Richard Kim, MD, episode 58. Dr. Kim is a board-certified physician specializing in nonsurgical orthopedic and regenerative medicine, in particular, platelet-rich plasma and stem cell therapy. He uses a rare combination of clinical training and research experience to diagnose musculoskeletal problems for which he develops a unique treatment plan for his patients. Dr. Kim has a refreshingly laid-back, personal vibe which he attributes to his West Coast upbringing. In combination with his high degree of compassion and commitment to personalized care, he is dedicated to helping his clients return to their active lifestyles through the highest standard of care as well as the newest technology available. How does creativity appear within his practice? As a business owner, Dr. Kim has developed a unique approach to growing a non-traditional practice. As a physician, creativity is essential in solving patient symptoms through skillful interpretation and examination. Dr. Kim is Board Certified in Internal medicine and Pediatrics with a Certificate of Added Qualification in Sports Medicine. He is also the Team Physician (10 years and counting!) for USA Rugby. He completed his medical training through Albany Medical College, completed a Sports Medicine Fellowship and received his undergraduate degree from University of Washington. To find out more about Dr Kim, please visit https://richardkimmedicine.com. You can also find him on Facebook: @richardkimmedicine and on Instagram: https://www.instagram.com/richardkimmedicine/. -Creativity Conversations explores the nature of our infinite creative potential. Creativity is as simple as being open and curious, creating interesting things, solving problems, finding solutions and being in the “flow”. It's essence is always and everywhere the same. - Nina Lockwood is a coach, author, speaker and artist who helps people hungry for positive life changes find new direction and purpose and live more fulfilling lives. - #ninalockwood #richardkimmedicine #creativityconversations #creativity #regenerativemedicine #plateletrichplasma #stemcelltherapy #USARugby #compassionatemedicalcare #humanityinmedicine #EpisodeDropped #PodCreator #PodHelp #PodernFamily

Sensei Randy joins us as we finish the trilogy on the teachers of Master Peter Urban with a look at the enigma that is Richard Kim. We touch on the pros and cons, ups and downs, controversies and successes of his life. Wow -that's all I can say - well that and Thanks for listening!

Following a series of developments in the battery industry in recent weeks, IHS Markit deep dives into the impact and significance they are expected to have. These include Nissan and Envision AESC's plan to build the UK's first gigafactory adjacent to the OEM's Sunderland plant, where it will also manufacture a new electric vehicle. Our experts discuss the importance this has on the British automotive industry, as well as whether or not there is scope to then export the batteries to the European Union and beyond. Stellantis was another carmaker that recently hit the headlines after hosting its own EV Day, where it signaled an introduction of solid state batteries from 2026. Our experts question whether this timeline will put it at the forefront of the technology's use on a mass scale. And finally, this week's episode will also explore how the battery market will progress in the long term, including if current-day lithium-ion batteries have reached their maximum potential as alternative cell materials and compositions develop. Speakers: Graham Evans, E-Mobility research and analysis director at IHS Markit Amit Panday, E-Mobility news correspondent at IHS Markit Dr. Richard Kim, Battery expert at IHS Markit We'd love to hear your thoughts on this episode at our autology@ihsmarkit.com email, and you can find out much more across the autotechinsight.ihsmarkit.com website. Don't forget to hit all the subscribe, follow and like buttons to stay on track with the latest Autology podcasts!

In this podcast, we talk and learn about Climate Justice with Richard Kim and Yang Hong from the community Work on Climate Some of the topics we'll be discussing include: - The “Work on Climate” community and its goal - The guide “Climate Justice 101” and the reasons for creating it - The different definitions of climate justice - The risk that technology perpetuates climate injustice - Intersectional environmentalism as an imperative to the fight against climate change - What we can do to integrate climate justice into our projects - Data justice and equity References: * [Climate Justice Guide 101](http://bit.ly/CJ-101) * [Work on Climate Starter Packs](https://www.notion.so/workonclimate/Starter-Packs-Community-curated-resources-52547bba557e4544bacc299d3a077795) * H. Moore & J.K. Russell, [Organizing Cools the Planet](https://climateaccess.org/system/files/Moore%20and%20Russell_Organizing%20Cools%20the%20Planet.pdf) * [BlocPower](http://blocpower.io/) * [GreenWave](https://www.greenwave.org/) * [Dr. Ayana Elizabeth Johnson](https://www.ayanaelizabeth.com/), "[How to Save a Planet](https://gimletmedia.com/shows/howtosaveaplanet/)" * [WeACT](https://www.weact.org/) On positionality and climate justice as a personal practice in community: * [On positionality](https://www.arteachingcollective.com/positionality.html) * [Bad Activist Collective](https://www.badactivistcollective.com/) * "[My Role in a Social Change Ecosystem](https://dviyer.medium.com/my-role-in-a-social-change-ecosystem-a-mid-year-check-in-1d852589cdb1)" by [Deepa Iyer](http://deepaiyer.com/) * "[Pod Mapping](https://batjc.wordpress.com/resources/pods-and-pod-mapping-worksheet/)" for accountability by [Mia Mingus](https://leavingevidence.wordpress.com/about-2/) * "[Everything worthwhile is done with other people](https://adimagazine.com/articles/mariame-kaba-everything-worthwhile-is-done-with-other-people/)" -- [Mariame Kaba](https://forthewild.world/listen/mariame-kaba-on-moving-past-punishment-151) * A few climate communities with members from tech: [Work On Climate](https://workonclimate.org/), [Climate Action Tech](https://climateaction.tech/), [Terra.do](http://terra.do/) * Daily practice: [Anti-Racism Daily](https://www.antiracismdaily.com/), "[Practical Decolonization: How to live it daily](https://everydayfeminism.com/practical-decolonization/)" workshop On data (in)justice and the dangers of uncritical tech and data in climate: * [Data Harm Record](https://datajusticelab.org/data-harm-record/) of harms from data and algorithms from the [Data Justice Lab](https://datajusticelab.org/) * "[False solutions](https://media.wix.com/ugd/75b7f5_2c41011de1a84177ad9aaf477db50566.pdf)" to climate change ([here's a short sample](http://jtalliance.org/wp-content/uploads/2020/02/False-Solutions.pdf)) * [Data Capitalism](https://datacapitalism.d4bl.org/) interactive from Data 4 Black Lives * “[Decolonizing Methodologies: 20 Years On](https://www.youtube.com/watch?v=YSX_4FnqXwQ)” annual lecture by [Professor Linda Tuhiwai Smith](https://www.waikato.ac.nz/maori/linda-tuhiwai-smith) On the importance of intersectional climate justice: * [Intersectional Environmentalism](https://www.intersectionalenvironmentalist.com/) by [Leah Thomas](https://www.greengirlleah.com/) * [Who Killed Berta Cáceres?](https://www.theguardian.com/world/2020/jun/02/who-killed-berta-caceres-behind-the-brutal-of-an-environment-crusader) * "[Indigenous sovereignty could save the planet](https://truthout.org/articles/un-report-says-indigenous-sovereignty-could-save-the-planet/)" Principles aligning across movements: * [A Just Transition Framework](https://climatejusticealliance.org/just-transition/) from the [Climate Justice Alliance](https://climatejusticealliance.org/) * [Design Justice Principles](https://designjustice.org/read-the-principles) (en [français](https://designjustice.org/french))

Every Sunday, Christians all over the world recite the Nicene Creed as a confession of faith. While most do not know the details of the controversy that led to its composition, they are aware that the Council of Nicaea was a critical moment in the history of Christianity. For scholars, the Council has long been a subject of multi-disciplinary interest and continues to fascinate and inspire research. As we approach the 1700th anniversary of the Council, The Cambridge Companion to the Council of Nicaea (Cambridge UP, 2021) provides an opportunity to revisit and reflect on old discussions, propose new approaches and interpretative frameworks, and ultimately revitalize a conversation that remains as important now as it was in the fourth century. The volume offers fifteen original studies by scholars who each examine an aspect of the Council. Informed by interdisciplinary approaches, the essays demonstrate its profound legacy with fresh, sometimes provocative, but always intellectually rich ideas. Zach McCulley (@zamccull) is a historian of religion and literary cultures in early modern England and PhD candidate in History at Queen's University Belfast. Learn more about your ad choices. Visit megaphone.fm/adchoices

Every Sunday, Christians all over the world recite the Nicene Creed as a confession of faith. While most do not know the details of the controversy that led to its composition, they are aware that the Council of Nicaea was a critical moment in the history of Christianity. For scholars, the Council has long been a subject of multi-disciplinary interest and continues to fascinate and inspire research. As we approach the 1700th anniversary of the Council, The Cambridge Companion to the Council of Nicaea (Cambridge UP, 2021) provides an opportunity to revisit and reflect on old discussions, propose new approaches and interpretative frameworks, and ultimately revitalize a conversation that remains as important now as it was in the fourth century. The volume offers fifteen original studies by scholars who each examine an aspect of the Council. Informed by interdisciplinary approaches, the essays demonstrate its profound legacy with fresh, sometimes provocative, but always intellectually rich ideas. Zach McCulley (@zamccull) is a historian of religion and literary cultures in early modern England and PhD candidate in History at Queen's University Belfast. Learn more about your ad choices. Visit megaphone.fm/adchoices

Every Sunday, Christians all over the world recite the Nicene Creed as a confession of faith. While most do not know the details of the controversy that led to its composition, they are aware that the Council of Nicaea was a critical moment in the history of Christianity. For scholars, the Council has long been a subject of multi-disciplinary interest and continues to fascinate and inspire research. As we approach the 1700th anniversary of the Council, The Cambridge Companion to the Council of Nicaea (Cambridge UP, 2021) provides an opportunity to revisit and reflect on old discussions, propose new approaches and interpretative frameworks, and ultimately revitalize a conversation that remains as important now as it was in the fourth century. The volume offers fifteen original studies by scholars who each examine an aspect of the Council. Informed by interdisciplinary approaches, the essays demonstrate its profound legacy with fresh, sometimes provocative, but always intellectually rich ideas. Zach McCulley (@zamccull) is a historian of religion and literary cultures in early modern England and PhD candidate in History at Queen's University Belfast. Learn more about your ad choices. Visit megaphone.fm/adchoices

Every Sunday, Christians all over the world recite the Nicene Creed as a confession of faith. While most do not know the details of the controversy that led to its composition, they are aware that the Council of Nicaea was a critical moment in the history of Christianity. For scholars, the Council has long been a subject of multi-disciplinary interest and continues to fascinate and inspire research. As we approach the 1700th anniversary of the Council, The Cambridge Companion to the Council of Nicaea (Cambridge UP, 2021) provides an opportunity to revisit and reflect on old discussions, propose new approaches and interpretative frameworks, and ultimately revitalize a conversation that remains as important now as it was in the fourth century. The volume offers fifteen original studies by scholars who each examine an aspect of the Council. Informed by interdisciplinary approaches, the essays demonstrate its profound legacy with fresh, sometimes provocative, but always intellectually rich ideas. Zach McCulley (@zamccull) is a historian of religion and literary cultures in early modern England and PhD candidate in History at Queen's University Belfast.

Every Sunday, Christians all over the world recite the Nicene Creed as a confession of faith. While most do not know the details of the controversy that led to its composition, they are aware that the Council of Nicaea was a critical moment in the history of Christianity. For scholars, the Council has long been a subject of multi-disciplinary interest and continues to fascinate and inspire research. As we approach the 1700th anniversary of the Council, The Cambridge Companion to the Council of Nicaea (Cambridge UP, 2021) provides an opportunity to revisit and reflect on old discussions, propose new approaches and interpretative frameworks, and ultimately revitalize a conversation that remains as important now as it was in the fourth century. The volume offers fifteen original studies by scholars who each examine an aspect of the Council. Informed by interdisciplinary approaches, the essays demonstrate its profound legacy with fresh, sometimes provocative, but always intellectually rich ideas. Zach McCulley (@zamccull) is a historian of religion and literary cultures in early modern England and PhD candidate in History at Queen's University Belfast. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/religion

Every Sunday, Christians all over the world recite the Nicene Creed as a confession of faith. While most do not know the details of the controversy that led to its composition, they are aware that the Council of Nicaea was a critical moment in the history of Christianity. For scholars, the Council has long been a subject of multi-disciplinary interest and continues to fascinate and inspire research. As we approach the 1700th anniversary of the Council, The Cambridge Companion to the Council of Nicaea (Cambridge UP, 2021) provides an opportunity to revisit and reflect on old discussions, propose new approaches and interpretative frameworks, and ultimately revitalize a conversation that remains as important now as it was in the fourth century. The volume offers fifteen original studies by scholars who each examine an aspect of the Council. Informed by interdisciplinary approaches, the essays demonstrate its profound legacy with fresh, sometimes provocative, but always intellectually rich ideas. Zach McCulley (@zamccull) is a historian of religion and literary cultures in early modern England and PhD candidate in History at Queen's University Belfast. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/christian-studies

Every Sunday, Christians all over the world recite the Nicene Creed as a confession of faith. While most do not know the details of the controversy that led to its composition, they are aware that the Council of Nicaea was a critical moment in the history of Christianity. For scholars, the Council has long been a subject of multi-disciplinary interest and continues to fascinate and inspire research. As we approach the 1700th anniversary of the Council, The Cambridge Companion to the Council of Nicaea (Cambridge UP, 2021) provides an opportunity to revisit and reflect on old discussions, propose new approaches and interpretative frameworks, and ultimately revitalize a conversation that remains as important now as it was in the fourth century. The volume offers fifteen original studies by scholars who each examine an aspect of the Council. Informed by interdisciplinary approaches, the essays demonstrate its profound legacy with fresh, sometimes provocative, but always intellectually rich ideas. Zach McCulley (@zamccull) is a historian of religion and literary cultures in early modern England and PhD candidate in History at Queen's University Belfast. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/biblical-studies

Every Sunday, Christians all over the world recite the Nicene Creed as a confession of faith. While most do not know the details of the controversy that led to its composition, they are aware that the Council of Nicaea was a critical moment in the history of Christianity. For scholars, the Council has long been a subject of multi-disciplinary interest and continues to fascinate and inspire research. As we approach the 1700th anniversary of the Council, The Cambridge Companion to the Council of Nicaea (Cambridge UP, 2021) provides an opportunity to revisit and reflect on old discussions, propose new approaches and interpretative frameworks, and ultimately revitalize a conversation that remains as important now as it was in the fourth century. The volume offers fifteen original studies by scholars who each examine an aspect of the Council. Informed by interdisciplinary approaches, the essays demonstrate its profound legacy with fresh, sometimes provocative, but always intellectually rich ideas. Zach McCulley (@zamccull) is a historian of religion and literary cultures in early modern England and PhD candidate in History at Queen's University Belfast. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/intellectual-history

Every Sunday, Christians all over the world recite the Nicene Creed as a confession of faith. While most do not know the details of the controversy that led to its composition, they are aware that the Council of Nicaea was a critical moment in the history of Christianity. For scholars, the Council has long been a subject of multi-disciplinary interest and continues to fascinate and inspire research. As we approach the 1700th anniversary of the Council, The Cambridge Companion to the Council of Nicaea (Cambridge UP, 2021) provides an opportunity to revisit and reflect on old discussions, propose new approaches and interpretative frameworks, and ultimately revitalize a conversation that remains as important now as it was in the fourth century. The volume offers fifteen original studies by scholars who each examine an aspect of the Council. Informed by interdisciplinary approaches, the essays demonstrate its profound legacy with fresh, sometimes provocative, but always intellectually rich ideas. Zach McCulley (@zamccull) is a historian of religion and literary cultures in early modern England and PhD candidate in History at Queen's University Belfast. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

Every Sunday, Christians all over the world recite the Nicene Creed as a confession of faith. While most do not know the details of the controversy that led to its composition, they are aware that the Council of Nicaea was a critical moment in the history of Christianity. For scholars, the Council has long been a subject of multi-disciplinary interest and continues to fascinate and inspire research. As we approach the 1700th anniversary of the Council, The Cambridge Companion to the Council of Nicaea (Cambridge UP, 2021) provides an opportunity to revisit and reflect on old discussions, propose new approaches and interpretative frameworks, and ultimately revitalize a conversation that remains as important now as it was in the fourth century. The volume offers fifteen original studies by scholars who each examine an aspect of the Council. Informed by interdisciplinary approaches, the essays demonstrate its profound legacy with fresh, sometimes provocative, but always intellectually rich ideas. Zach McCulley (@zamccull) is a historian of religion and literary cultures in early modern England and PhD candidate in History at Queen's University Belfast. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In this episode, we speak with Richard Kim, General Partner, Galaxy Interactive, Andrey "Reynad" Yanyuk, Founder & CEO, Tempo Storm, and Sankar Krishnan, EVP, Banking & Capital Markets, Capgemini Financial Services, about the future of interactive gaming and esports and how they could potentially fit into banking.Visit the Future Sight website →

Hey everybody, Next with Novo is back, and we're trying something new. For the first time ever, we have two amazing guests on the show, Sam Englebardt and Richard Kim, both of whom are Partners at Galaxy Interactive, a part of Galaxy Digital dedicated to the interactive and entertainment sectors. In today's episode, we'll hear from both Sam and Richard about the Interactive strategy, why they got into it as early as they did, early NFT investments, as well as a discussion on the metaverse, social tokens, and what's coming in the future. Sam and Richard are two very smart individuals who are passionate about what they do and the intersection of finance, art, media, and interactive technology. This is an episode you don't want to miss. Tune in… you might learn a thing or two. Make sure to subscribe to my YouTube and Apple Podcasts channels so you don't miss out on future episodes, and follow me: Twitter: https://twitter.com/novogratz YouTube: www.youtube.com/c/mikenovo/ Spotify: https://spoti.fi/3sdPneD Next with Novo is the go-to resource for what's new and what's next. In this series, Mike Novogratz, influential investor, Wall Street Veteran, and CEO at Galaxy Digital, invites viewers to learn with him from the brightest minds behind disruptive businesses, prolific social movements, and technologies powering permissionless innovation. This podcast was recorded on May 27, 2021. The Next with Novo podcast is for informational purposes only. Nothing in this podcast constitutes an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities. The information in the podcast does not constitute investment, legal, or tax advice. The host is an affiliate of Galaxy Digital (host and Galaxy Digital together, the “Parties”), and the podcast represents the opinions of the host and/or guest and not necessarily that of Galaxy Digital. The Parties do not make any representation or warranty, express or implied, as to the accuracy or completeness of any of the information therein. Each of the Parties expressly disclaims any and all liability relating to or resulting from the use of this information. Certain information in the podcast may have been obtained from published and non-published sources and has not been independently verified. The Parties may buy, sell or hold investments in some of the companies, digital assets or protocols discussed in this podcast. Except where otherwise indicated, the information in this video is based on matters as they exist as of the date of preparation and will not be updated.

Former Goa'l Secretary General Richard Kim talks to Kaomi Lee of Adapted Podcast about the pros and cons of the F4 visa vs. dual citizenship for Korean adoptees. Information heard here is subject to change. Consult an immigration attorney or the Korean immigration office for final word. 

In the debut episode of the new Autology podcasts, we discuss how Formula E is driving technology for EVs on the road, including how OEMs-come-race-teams like Nissan and Jaguar Land Rover are applying their learnings in energy regeneration systems to their production vehicles. The sport has come a long way since the drivers were forced to change vehicles mid-race due to limited battery range, with the upcoming third generation Formula E race car including a fast-charging 350kW battery. However, the high cost of battery systems is still an issue both on and off the circuit – a point that that is explored in the podcast, alongside when the cost of batteries will be more sustainable. And then there's the question if we'll see the day without Formula 1 and other traditionally fueled racing car series? Tune in to reveal all, including the predicted year which our experts think will mark the end of the internal combustion engine. Speakers: Frederic Espinos, Sporting Director at Formula E Elisha Thakorlal, OEM strategy expert at IHS Markit Dr. Richard Kim, Battery expert at IHS Markit We'd love to hear your thoughts on this episode at our autology@ihsmarkit.com email – and you can find out much more across the autotechinsight.ihsmarkit.com website. Don't forget to hit all the subscribe, follow and like buttons to stay on track with the latest Autology podcasts!

In this episode, we speak with Richard Kim, General Partner, Galaxy Interactive, Andrey "Reynad" Yanyuk, Founder & CEO, Tempo Storm, and Sankar Krishnan, EVP, Banking & Capital Markets, Capgemini Financial Services, about the future of interactive gaming and esports and how they could potentially fit into banking.

This episode was made with help from Ben Lakoff, Co-Founder of Charged Particles and Richard Kim, Partner at Galaxy Interactive. Full length episode with Richard  dropping soon! LINKSEP 52: A Little NFTy Story | Part 1EP 53: A Little NFTy Story | Part 2EP 58: Unstacking with Charged Particles | Creating yield-bearing NFTsNFT Value Capture Equation by Cooper TurleyFOLLOW AMBER GROUPTwitter: https://twitter.com/ambergroup_ioEmail: contact@ambergroup.ioWebsite: https://www.ambergroup.io/DISCLOSURE The Crypto Unstacked Podcast is meant for informational purposes only and should not be considered as financial or investment advice. Nothing expressed in this podcast should be construed as a solicitation, recommendation, endorsement or offer by Amber Group to buy or sell any financial products. Information expressed by the host or guest in this podcast does not necessarily reflect the views of Amber Group.MUSIC CREDITSFloating Also: https://www.youtube.com/watch?v=HHYOBwzT4u4&list=PLwJjxqYuirCLkq42mGw4XKGQlpZSfxsYd&index=25#AmberGroup #NFT #CryptoUnstacked

In this episode of “On the Case,” Richard Kim, MD, MSc, joins us to discuss his case report about a patient who experienced hemolacria, or blood in tears.Kim is a regional anesthesiology and acute pain medicine fellow at Stanford University School of Medicine, in California.“On the Case” is an interview-driven podcast series, in which we take a behind-the-scenes look at the popular case reports that are published in Anesthesiology News. We discuss with the authors of those case reports what it was like to experience those clinical situations and why they decided to write about them afterward. This is the first episode of the series, and new episodes will be published every month. Links from episodeLink to case report: Just in Time for Halloween: Hemolacria, or Blood in TearsSubmit your case report here: AnesthesiologyNews.com/CaseSubmission 

Sam Englebardt and Richard Kim join Everything EOS to discuss their $325 EOS VC Fund, Galaxy Interactive. Galaxy Interactive is a venture fund investing at the intersection of interactive content, esports/gaming, digital objects and blockchain tech. www.galaxyinteractive.io ***Co-Hosts*** Chaney Moore Writer.io @moore_chaney Zack Gall Everything EOS / LiquidApps @BlockchainZack *** For more information on sponsorship opportunities or content partnerships, please contact zack@everythingeos.io https://www.EverythingEOS.io https://youtube.com/c/Everything_EOS http://t.me/Everything_EOS https://anchor.fm/everythingeos https://itunes.apple.com/us/podcast/everything-eos/id1434560651?mt=2

Sam Englebardt and Richard Kim join Everything EOS to discuss their $325 EOS VC Fund, Galaxy Interactive. Galaxy Interactive is a venture fund investing at the intersection of interactive content, esports/gaming, digital objects and blockchain tech. www.galaxyinteractive.io ***Co-Hosts*** Chaney Moore Writer.io @moore_chaney Zack Gall Everything EOS / LiquidApps @BlockchainZack *** For more information on sponsorship opportunities or content partnerships, please contact zack@everythingeos.io https://www.EverythingEOS.io https://youtube.com/c/Everything_EOS http://t.me/Everything_EOS https://anchor.fm/everythingeos https://itunes.apple.com/us/podcast/everything-eos/id1434560651?mt=2

As we seek to challenge the norms of automotive, we are emboldened by the success of the many artists and designers who go before us. In this episode, we chat with two legends in the industry and true disruptors, Rem D Koolhaas and Joey Ruiter. Co-hosted by Canoo's design chief Richard Kim.

You've heard it everywhere by now - it's a brave new world in gaming in 2020. And as people are more open than ever to finding ways to spend more time together online, there are thinkers who analyze these trends to figure out which companies and founders are worth investing time, energy - and of course, those big bucks - into. In E05 of Devoted Speakeasy, join host Ninel Anderson as she chats with Sam Englebardt, Managing Partner of Galaxy Interactive, Richard Kim, Partner at Galaxy Interactive, and William Rhys Dekle, Partner at Strategic Alternatives. Between them they've supported the likes of Mythical, Proletariat, DazzleRocks, and more. Find out how these decisions are made, straight from the minds of some of the industry's most experienced and thoughtful investors. 14 Things to Know to Raise Money in Gaming in 2020: 01) (01:50) 5 things investors are looking for in a pitch 02) (03:53) How do investors do their due diligence on content? 03) (07:43) The Pitch Process, and case studies from Galaxy's portfolio 04) (20:53) Cold calling investors vs. warm intro? 05) (22:42) Is building a “Founder Brand” a necessity? 06) (23:10) How to research investors? 07) (27:25) Are consultants helpful in raising money? 08) (29:17) Supporting each other is key! 09) (30:27) What is the difference between a lead investor and a follower? 10) (31:10) How do you price your business? 11) (36:05) Do your math! Is VC actually a good solution for you? What other options do you have? 12) (37:29) Overall time, from starting pitching, to term sheet draft, to final version. When would you actually receive the money in your account? 13) (38:55) What's the usual time between the rounds? What should the founder be doing in between rounds? 14) (42:52) How has the process changed with the advent of the pandemic? #devotedSpeakeasy #gaming #GamingVenture www.devotedstudios.com www.galaxyinteractive.io www.strataltllc.com

Host Piers Kicks sits down for Episode 06 of Metaverse Musings with Richard Kim, who is a general partner at Galaxy Interactive alongside Sam Englebardt. Across their sector focus, the fund has been the most active in the world over the last 12 months. Richard shared deep insights that are clearly the product of his unique positioning across the gaming landscape. It’s refreshing to see such strong conviction in the role that digital assets play in the metaverse from a large player with roots in both the traditional finance and video game industries.  Thank you to our sponsor Crypto.com for making this happen! Visit bit.ly/cryptodelphi for more information! – Resources: Galaxy Interactive: https://galaxyinteractive.io/ Richard’s Twitter: https://twitter.com/galaxyRTK Piers’ Twitter: https://twitter.com/pierskicks Delphi Podcast Twitter:   Matthew Ball’s essay on MILEs: https://www.matthewball.vc/all/cloudmiles  SignalFire Creator Economy Map: https://www.signalfire.com/blog/creator-economy/    Our Video interviews Can Be Viewed Here: https://youtu.be/fubeSokngY8 Access Delphi’s Research Here: https://www.delphidigital.io/   Disclosures: This podcast is strictly informational and educational and is not investment advice or a solicitation to buy or sell any tokens or securities or to make any financial decisions. Do not trade or invest in any project, tokens, or securities based upon this podcast episode. The host may personally own tokens that are mentioned on the podcast. Lets Talk Bitcoin is a distribution partner for the Chain Reaction Podcast, and our current show features paid sponsorships which may be featured at the start, middle, and/or the end of the episode. These sponsorships are for informational purposes only and are not a solicitation to use any product or service.

In this episode, Alan Kohll talks with Dr. Richard Kim, Vice President, Chief Medical Officer at American Express, about the changes they have made during the COVID-19 pandemic to keep employees healthy. Since the pandemic, Amex has really shown their employees that they have their backs and have pivoted to offer resources and services virtual. Amex has hosted a variety of webinars around topics such as coping with COVID-19, building resilience, providing insight and tips on how to speak to children about the pandemic and much more.

Today I'm talking with Richard Kim and Sam Englebardt, who are partners at Galaxy Interactive, a $325m fund shaping the future of interactive entertainment. Richard and Sam have been investing into gaming for a while now and in this episode, we discuss how they see financing in gaming evolving, what it takes to get into competitive rounds and how they see as key in the gaming space in the next 2-5 years.

We talk "Free Will" and "Love"... --- To reciprocate my spew and become a member of the DGAF Community, click here: https://www.patreon.com/DGAFPokerPlayer To get to the DGAF Community, click here: https://dgafcommunity.com To listen to previous seasons, click here: http://dgaf-sessions.libsyn.com  To get your Sessions apparel, click here: https://pokerrags.us

We talk "Free Will" and "Love"... --- To reciprocate my spew and become a member of the DGAF Community, click here: https://www.patreon.com/DGAFPokerPlayer To get to the DGAF Community, click here: https://dgafcommunity.com To listen to previous seasons, click here: http://dgaf-sessions.libsyn.com  To get your Sessions apparel, click here: https://pokerrags.us

I have a couple beers via satellite with the young philosopher from Skokie, IL... --- To reciprocate my spew and become a member of the DGAF Community, click here: https://www.patreon.com/DGAFPokerPlayer To get to the DGAF Community, click here: https://dgafcommunity.com To listen to previous seasons, click here: http://dgaf-sessions.libsyn.com 

Not another headache! But taking note of your symptoms and how often and how long headaches trouble you can provide vital information to relieve or even prevent them. In this Premier Health Now On-Air podcast, we talk about understanding and managing that pain in your head. You’ll learn what might trigger it, how your over-the-counter medication could make things worse, and an exciting new treatment to prevent migraines. Join headache specialist Dr. Richard Kim of the Clinical Neuroscience Institute for a healthy dose of pain relief.

Phillip Koeppel returns this week. Sensei Koeppel has practiced martial arts for over 60 years, training with Yoshio Kawaguchi and Richard Kim in Yokohama Japan, Adriano Emperado in Hawaii, and Robert Trias in the US, and now practices Matsumura Seito Ryu. He opened the first karate dojo in Illinois in 1959.   Today we start off by hearing how Mr. Koeppel met a fresh off the boat Bruce Lee, a few final thoughts on Kajukembo and Emperado, before getting into the difficulties of opening a karate dojo when nobody knows what karate is.  He then talks about working with Robert Trias to help popularize it in the US, and the early efforts to coordinate the Japanese, Okinawan, and American practitioners. 

This week's guest, Phillip Koeppel, is a true American Karate Pioneer.  Sensei Koeppel has been practicing martial arts for over 60 years.  Starting in 1956 in Yokohama Japan under Toshio Kawaguchi and Richard Kim, then moving on to Hawaii to train in Kajukembo with Adriano Emperado, before returing to Illinois and joining Robert Trias and the USKA.  His many credits include opening the first karate school in Illinois, organizing the first tournament in the midwest, and founding the United States Karate-Dp Kai.  He has been involved with every stage of karate's development in the US.

Richard Kim is a tech marketer and a man on a mission. He started the Gen Z foundation to leverage our generation’s potential for impact, and is passionate about making the world a better place. Follow him on LinkedIn: https://www.linkedin.com/in/imrichkim/ Summer of Transformation book Canada: https://www.amazon.ca/dp/B07DZ3ZT9N Summer of Transformation book US: https://www.amazon.com/dp/B07DZ3ZT9N LET’S CONNECT: WEBSITE:

Welcome to another episode of Biotechnology Focus radio. I am your host – Michelle Currie – here to give you the rundown on the Canadian biotech scene. This week I’ll be discussing how the regenerative medicine community is abuzz, expanding personalized medicine, and the very recent announcement from the Ontario government that brings great news to the life sciences sector.   +++++  The regenerative medicine field, which includes cell and gene therapies (CGTs), is still abuzz with the fall approvals of three CGTs by the U.S. Food and Drug Administration: Novartis’ Kymriah, Gilead/Kite Pharma’s Yescarta and Spark Therapeutics Inc.’s Luxturna.  At the Cell and Gene Therapy World conference in Miami, Florida (January 22-25), many of the talks were either about the approved treatments or congratulating the industry on these significant milestones.  Reni Benjamin, of Raymond James Financial, reminded delegates that the pharmaceutical industry is also feeling confident about cell and gene therapes s. Acquisitions in 2017 were worth billions: Gilead acquired Kite for $11.9 billion, Takeda bought Ariad for $5.2 billion and Roche acquired Ignyta for $1.7 billion. As the conference was just getting underway, the news was announced that Celgene is buying Juno Therapeutics for $9 billion.  Illustrating the future of the field are the more than 1,300 currently open clinical trials listing stem cells (from sources other than blood) as the primary therapeutic, the 1,000 clinical trials in gene therapy, and clinical trials involving chimeric antigen receptor (CAR) T cells (a type of immune system cell) accounted for around half of clinical trials in 20162.  As such, global investment in the cell and gene therapies and regenerative medicine industry is booming. For example, public and private investment in immuno-oncology has grown to $1.5 billion2. When it comes to gene therapies, the forecast for the year 2025 ranges from $4.3 billion to $10 billion2 due to recent advances in the understanding of genetic disease, and innovation in genetic engineering tools. Altogether, it is estimated that the regenerative medicine industry will explode to a valuation of up to $20 billion by the year 2025.     So, where does Canada sit in terms of being an innovator in these advanced therapeutic technologies?     Let’s start with the good news. Canada is a prominent force in this emerging global field. We have a strong backbone of Canada-based researchers who are recognized scientific leaders, and a robust system for the development of highly-qualified personnel through Canada’s universities. We have also benefited from strategic investments in research, collaborative networks and infrastructure, and are developing a deep understanding of how to translate these advanced therapies from the bench to the bedside.  One way to sustain Canada’s leadership position is to nurture the right skills and education within our borders. Encouraging STEM (science, technology, engineering and mathematics) education from a young age is a necessary first step. Extending STEM-based education with biomedical engineering programs at the university level is a good strategy for supporting the growth of Canada’s CGT and regenerative medicine industry. Biomedical engineering – where engineering design principles and mathematics are applied to medicine and biology, allowing students to make significant contributions to improving human health by finding new diagnostic or therapeutic solutions – is an area Canadian universities are increasingly focusing on.  An illustration of how biomedical engineers are already impacting the regenerative medicine field can be found at the University of Toronto’s Institute of Biomaterials and Biomedical Engineering (IBBME) and at Medicine by Design. The 55-year-old IBBME fosters a multidisciplinary research community where students and investigators in engineering, medicine and dentistry collaborate to develop innovative solutions that address global challenges in human health. Their impact can be seen in the development of breakthrough biomedical devices and new biomaterial products.  Funded in 2015 with a generous federal grant, Medicine by Design builds on IBBME’s successful multidisciplinary model to conceive, create and test strategies to address critical problems in regenerative medicine. By working across disciplines and generating and using emerging methods, like genome editing, computational modelling and synthetic biology, Medicine by Design is generating a deeper understanding of core biological concepts controlling stem cell fate, and devising new therapeutic approaches that will improve health outcomes.  This successful approach is now receiving a significant boost in Vancouver, where the University of British Columbia (UBC) has launched a new School of Biomedical Engineering as a partnership between the Faculty of Medicine and the Faculty of Applied Science.     Centre of commercialization and regenerative medicine, a Toronto-based leader in developing and commercializing regenerative medicine technologies, understands how the intersection of engineering and medicine, introduced by biomedical engineers, can help provide the tools that will advance the industry now and into the future.  One area where Centre of commercialization and regenerative medicine employs biomedical engineers is in its Centre for Advanced Therapeutic Cell Technologies (CATCT), a joint investment by GE Healthcare and the Government of Canada. Biomedical engineers work on process development strategies and solutions, and on projects involving reprogramming and engineering cells, immunotherapies and gene therapies. Operational for over a year, Centre for Advanced Therapeutic Cell Technologies was created to accelerate the development and adoption of cell manufacturing technologies that improve patient access to novel regenerative medicine-based therapies. The team introduces new technologies to solve emerging technical challenges and closes gaps in current and future workflows.      Our next challenge is to make certain that we have the people, technologies, processes and infrastructure to ensure Canadians have equitable access to these potentially game-changing therapies. Biomedical engineering programs are a start. Engineers are trained to look for efficiencies through cost reductions and improved technologies.  We need to build a Canadian innovation cluster that will attract talent and business expertise to capture the intellectual property developed in Canada and mobilize it for the benefit of Canadians.  We also need to work with government to position our health-care system as part of our competitive advantage. A big part of getting to this step in getting to this solution is starting to look at health economic models that integrate therapeutic costs and savings from development through to long term patent treatment costs.  Together, Canada’s companies, networks, researchers, start-ups and innovative centres are starting to deliver on the promise of regenerative medicine. With the technical know-how and a spirit of collaboration, biomedical engineers are a driving force in the country’s quest to lead the regenerative medicine industry into the future.  +++++  Personalized medicine is becoming a very popular term heard amongst researchers and the scientific community. It is a more tailored approach to preventing disease that is based on an individual’s predispositions. Whichever way you put it – personalized medicine, genomic medicine, precision medicine – it is reshaping healthcare.  Dr. Richard Kim, a scientist at Lawson Health Research Institute and clinical pharmacologist at London Health Sciences Centre (LHSC), has received $4.4 million to study an expanded personalized medicine program at London Health Sciences Centre. One-third of the funding comes from the provincial government’s Ontario Research Fund (ORF) while the remainder is contributions from Thermo Fisher Scientific and donor funding through London Health Sciences Foundation.  Personalized medicine uses pharmacogenomics – the study of genetic changes that alter the way a person responds to individual drugs. The new funding will enable researchers to follow patient outcomes and assess the cost-effectiveness of London Health Sciences Centre’s personalized medicine program, providing evidence on the relationship between the cost of the program and how patient care is improved.  London Health Sciences Centre’s personalized medicine program involves the full integration of research into patient care and was the first in Canada to implement personalized medicine as a clinical strategy. The practice began in 2008 through Dr. Kim’s research on warfarin – a blood thinner prescribed to treat blood clots.  Adverse drug reactions in patients is a significant problem. Some drugs do not metabolize with every patient, and can even lead to toxicity. It is the fourth leading cause of death among hospitalized patients and costs the Canadian health care system over $5 billion a year.  Dr. Kim explains, “For every medication, there are patients who should be prescribed lower or higher than the recommended standard dose and patients who should be prescribed an entirely different medication. Personalized medicine studies a patient’s unique DNA to ensure he or she is prescribed the right dose of the right medication at the right time.”  The team’s research continues to grow since inception and is providing testing for several other drugs. For example, they can now offer testing for cancer patients that have been prescribed 5-fluorouracil – a highly toxic form of chemotherapy – but is integral in treating bowel, stomach, head, and neck cancers.  Oncologists at London Health Sciences Centre’s London Regional Cancer Program can now refer patients to get tested for their potential reaction to 5-fluorouracil to better predict if they may or may not have an adverse reaction. A blood sample will be taken and tested with genotyping, and a full report given to the recommending oncologist. If a patient’s predicted to react poorly with the drug, they can follow clinical guidelines to either reduce the dose or find a method of treatment.  The team will study the outcomes of any patients referred to the program, including hospital stays, emergency department visits, and physician visits. These patients will be compared to others in the province using provincial health care data from the Institute for Clinical Evaluative Sciences (ICES). The team hopes to demonstrate the cost-effectiveness of implementing personalized medicine in a large acute-care hospital in Ontario.  +++++  The most recent announcement from the government of Ontario this past week was that it is investing $50 million in venture capital funds focused on life sciences.  Ontario is moving forward with their plan for a venture capital fund to aid life sciences firms access the capital they need to grow their business, create jobs, and grow on a global level.  The Ontario Capital Growth Corporation (OCGC) would like to identify fund managers to partner with other institutional investors such as corporations, banks and pension funds. Ontario’s new life sciences venture capital fund is designed to respond to the challenges faced in raising capital by innovative, high-potential life sciences companies to scale up and reach global markets.  The Hon. Reza Moridi, Minister of Research and Innovation says, “Providing much needed capital to growing life sciences companies is a crucial step towards a strong and sustainable life sciences ecosystem. Supporting high-potential life sciences companies will create good jobs and help commercialize technologies and services for improved healthcare at home and around the world.”  Ontario’s new venture capital fund focused on life sciences is designed to respond to the challenges faced in raising capital by innovative, high-potential life sciences companies to scale up and reach global markets. It will also help businesses foster new discoveries, including new technologies, treatments and cures for illnesses while supporting high quality, knowledge-based jobs for people across the province. It will also drive Ontario’s ability to attract and retain talent.  The Ontario Capital Growth Corporation, venture capital agency of the government of Ontario, was created to promote and develop the venture capital sector in Ontario, so that more high-potential technology companies have access to the capital needed to grow and prosper.  Supporting innovation in the life sciences is part of Ontario’s plan to create fairness and opportunity during this period of rapid economic change. The plan includes a higher minimum wage and better working conditions, free tuition for hundreds of thousands of students, easier access to affordable child care, and free prescription drugs for everyone under 25 through the biggest expansion of medicare in a generation.  Ontario is the largest life sciences jurisdiction in Canada with more than 50 per cent of overall Canadian revenue. The province includes an incredible 1,840 firms employing close to 61,000 people across the province. This fund will open many doorways for Canadians and Ontarians.   +++++  Well, that wraps up another episode of Biotechnology Focus radio. I hope you enjoyed it. If you have a story idea or would like to be on the show, please email me at press@promotivemedia.ca. To see the articles in full check out the website biotechnologyfocus.ca ca so you don’t miss a beat! Have a momentous week. From my desk to yours – this is Michelle Currie.

Gabe chats with Richard Kim, founder of My Video Series, about the skills and traits that go into becoming both an entrepreneur and a good person. As he explains it, varied experiences and excellent mentors put Richard on a path to success. Early Introduction to Business   Richard started honing his sales skills in high school. As he grew older, his business intuition evolved, too. Richard was unaware at the time, but he has a strong sales ability that he has always managed to put to good use. School and Internship Experiences While attending college and studying marketing, Richard identified a disconnect in the internship program. Internships deliver a definite value, but matching students to small businesses was virtually impossible. The clear solution to Richard was to start a website connecting college students to local small businesses. Learning on the Job    After school, Richard took a position at Hyperloop One, an experience which greatly changed his perspective. He oversaw a team and gained valuable experience in terms of marketing, leadership and networking. Around this time, Richard came to a realization that successful people have useful knowledge to share. This knowledge could benefit Richard, but it can also benefit others. Richard brought his vision to life and began My Video Series. Through determination and persistence, Richard lined up interviews with successful individuals. The objective was to learn from the experiences of business titans. Surround Yourself with Successful People The people you surround yourself with matters a great deal. Richard cites mentors who push him to grow and learn as a key element to his development as a person and an entrepreneur. Successful people understand the process and can provide invaluable guidance. If You Want to Be Successful, Be Persistent Various traits contribute to success, but vision and leverage have greatly helped Richard reach his goals and ambitions. The desire to be a good person and help others are also driving forces in Richard’s life. When others invested their time, energy and wisdom to help Richard, he benefited, and now he wants to help others in this same way. Turning the Tables Towards the end of the discussion, Richard’s interviewing instincts came through, and he posed several questions to Gabe. Learn about Gabe’s entrepreneurial journey and how he used persistence and a desire to help others to build his business. Connect with Richard via email or social media. Catch up on earlier episodes of Today’s Business Leaders and learn more about the courses and solutions available via Gabe’s company.  

Richard Kim, MD from the Clinical Neuroscience Institute reviews migraine treatments and devices.

Bro. Richard Kim

Bro. Richard Kim

Bro. Richard Kim

Bro. Richard Kim

Bro. Richard Kim

Bro. Richard Kim

Bro. Richard Kim

We're taking a break from One-to-One this week to set off fireworks and contemplate the potential future of a Trump Presidential Center. In the meantime, we present some of our favorite episodes related to this big ol' hot mess of a nation. We've got it all:   "Traditional" architecture, not necessarily just like Jefferson would have wanted: Building Our Best Nature: Archinect Sessions One-to-One #8 with Scott Merrill, winner of this year's Driehaus Prize The too-common tragedy of mass shootings: Queer Space, After Pulse: Archinect Sessions #69 ft. special guests James Rojas and S. Surface Seeing through anti-LGBTQ legislation: Due Protest: pushing back against HB-2 and fighting for interns on Archinect Sessions #64, ft. special guest Gregory Walker Gun-control in the classroom: Guns in the Studio: Texas' new campus carry law prompted Architecture Dean Fritz Steiner to resign. He joins us to discuss the law's effect on architecture education, on Archinect Sessions #55 Public health crises from compromised infrastructure: Dispatch from Flint: How architects can help, on Archinect Sessions #54 Good ol' American architecture institutions: Inside the Institute: Archinect Sessions goes to the AIA National Convention on Episode #30 Interview with the architects who would become the designers for Obama's Presidential Center: "Starts with me, ends with us": A conversation with Tod Williams and Billie Tsien on Archinect Sessions Episode #22 and, of course, hot dogs: Hot Dogs Around the World: James Biber, architect of US Pavilion "American Food 2.0" at EXPO Milan, joins us for Episode #31 of Archinect Sessions I (Amelia) also personally recommend you check out these prior One-to-One's: The "Impossible" Car – Faraday Future's lead designer, Richard Kim, on One-to-One #17 The Ascendancy of Theory: writer and theorist Sylvia Lavin on Archinect Sessions One-to-One #13 The Art of Architecture Criticism: Archinect Sessions One-to-One #7 with Michael Kimmelman, architecture critic for the New York Times Our brand new interview podcast "Archinect Sessions One-to-One" premieres today! Listen to episode #1 with Neil Denari  

Richard Kim comes on the show to break down the Carson Wentz pick by the Eagles and why he thinks they should not have bet the house on him. Rich is an awesome guest, and this is a must listen!! His business thekimlawfirmllc.com is a proud sponsor of my radio show- Sam's Sports Show. Saturdays at 10am EST at 610amsports.com Email me at samssportsstation@gmail.com with mailbag questions and feedback. Like my Facebook page: https://www.facebook.com/samssportsstation/ Tweet at me: @smithfacejones

Great talk with our friend Richard Kim. If you're looking to be connected with a business in your field check out Richard's company Our Iterations. Website: http://ouriterations.com Email: letstalk@ouriterations.com

Richard Kim is a pretty busy guy – as the head designer at emerging electric vehicle company, Faraday Future, Kim is tasked with creating the company's very first EV for production, destined to compete with Tesla and, as he sees it, the airline industry. No public design is available yet, but Kim hopes to do the "impossible" and ready the car for production in 2017. We found some time in his tight schedule to discuss his role at Faraday Future and what's in store for car ownership and operation in the coming years, as automation and electric battery capabilities open up new paradigms for the humble automobile.

When most car design grads start out they dream about going to work at a famed Italian design house, or favorite brand. For Richard Kim, who heads automotive start-up Faraday Future’s design, it wasn’t just about the brand or the heritage.

This week on CounterSpin: The DEA made a high profile announcement of massive seizures of opium in Afghanistan, reminding us of the centrality of opium production to the country's economy. But most stories on the occupation and on Afghan ‘hearts and minds' include marginal mention of the narcotic. How would really understanding the role of opium shift our understanding of US policy in Afghanistan? We'll hear from historian Alfred McCoy, author of the classic The Politics of Heroin in Southeast Asia, now updated as The Politics of Heroin: CIA Complicity in the Global Drug Trade.   Also on CounterSpin today, it's not hard to show that Fox News host and radio talker Glenn Beck is a bit wacky– he spends several hours every day demonstrating as much. But the paranoid theories he's espousing have real consequences. So where do they come from? Richard Kim from the Nation tried to track one of Beck's favorite conspiracies, and he'll join us to tell us how the White House's political strategy is based on an article published in the Nation 40 years ago. It all makes perfect sense The post Counterspin – April 2, 2010 appeared first on KPFA.

Richard Kim, Senior Editor of The Nation and co-editor of Going Rouge speaks with Nicole Sandler about their new book about Sarah Palin